Forbion, a leading European life sciences venture capital firm, announces that Dr. John Montana has joined Forbion as Operating Partner, effective 1st January 2020.
Naarden, The Netherlands and Munich, Germany – 29 January 2020 – Forbion, a leading European life sciences venture capital firm, today announces that Dr. John Montana has joined Forbion as Operating Partner, effective 1st January 2020.
Currently, Forbion is in investment mode with its latest EUR 360 million Forbion IV fund, therefore, John’s main role will be in-sourcing, reviewing and managing new investment opportunities especially focused on Forbion’s company-building strategy.
John joins Forbion from Charles River Labs, where he oversaw all aspects of partnered, integrated drug discovery projects, ensuring their scientific progression from early business development discussions through to the delivery of quality clinical candidates. Previously, he was Managing Director at Argenta, responsible for all the scientific and operational aspects of the company. Prior to that, he was CSO of Paradigm Therapeutics before their acquisition by Takeda. During his career, John has overseen the delivery of over 60 development compounds for various organizations.
John is a member of the Royal Society of Chemistry, and his research has appeared in over 150 peer-reviewed papers and patents.
Sander Slootweg, Managing Partner at Forbion, said:
“Dr. John has an impressive track record of contributing to large pharma, biotech and contract research organizations through all stages of drug discovery and development. His proven leadership combined with his scientific acumen will be instrumental as we continue to build Forbion’s portfolio and deliver value to investors.”
Commenting on his appointment, Dr. John Montana, added:
“It’s a privilege to join such a strong team and I look forward to use my drug discovery and development experience to strengthen Forbion’s strong scientific and investment pedigree.”
- ENDS -
Notes To Editors
About Forbion
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 60 companies. Forbion manages well over EUR 1 billion across ten funds.
Forbion is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI) facilities and AMUF facilities and the KFW through the ERP – Venture Capital Fondsfinanzierung facility. Forbion operates a joint venture with BGV, the manager of seed and early stage funds focused on Benelux and Germany.
For more information, please visit: www.forbion.com.
Issued for and on behalf of Forbion by Instinctif Partners.
For more information please contact:
Forbion contact:
Sander Slootweg, Managing Partner
P: +31 (0) 35 699 30 00
E: sander.slootweg@forbion.com
Media contact:
Instinctif Partners
Melanie Toyne-Sewell/Ashley Tapp/Kiki Zaccagnini
P: +44 (0) 20 7457 2020
E: forbion@instinctif.com
